Cargando…

The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus

OBJECTIVE: Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular events and decrease the body fat mass in patients with type 2 diabetes mellitus (T2DM). We examined whether or not the SGLT2-inhibitor dapagliflozin can improve the endothelial function associated with a reduction in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugiyama, Seigo, Jinnouchi, Hideaki, Kurinami, Noboru, Hieshima, Kunio, Yoshida, Akira, Jinnouchi, Katsunori, Nishimura, Hiroyuki, Suzuki, Tomoko, Miyamoto, Fumio, Kajiwara, Keizo, Jinnouchi, Tomio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120841/ https://www.ncbi.nlm.nih.gov/pubmed/29607968 http://dx.doi.org/10.2169/internalmedicine.0701-17

Ejemplares similares

Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus
por: Sugiyama, Seigo, et al.
Publicado: (2018)

Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes
por: Sugiyama, Seigo, et al.
Publicado: (2018)

A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus
por: Sugiyama, Seigo, et al.
Publicado: (2015)

Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center
por: Sugiyama, Seigo, et al.
Publicado: (2019)

Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Jinnouchi, Hideaki, et al.
Publicado: (2015)

Clinical Factors Associated with Initial Decrease in Body-Fat Percentage Induced by Add-on Sodium-Glucose Co-transporter 2 Inhibitors in Patient with Type 2 Diabetes Mellitus
por: Kurinami, Noboru, et al.
Publicado: (2017)

Initial Acute Decline in Estimated Glomerular Filtration Rate After Sodium-Glucose Cotransporter-2 Inhibitor in Patients With Chronic Kidney Disease
por: Sugiyama, Seigo, et al.
Publicado: (2020)

Elevation of the renal threshold for glucose is associated with insulin resistance and higher glycated hemoglobin levels
por: Hieshima, Kunio, et al.
Publicado: (2020)

Smoking Cessation Ameliorates Microalbuminuria With Reduction of Blood Pressure and Pulse Rate in Patients With Already Diagnosed Diabetes Mellitus
por: Hieshima, Kunio, et al.
Publicado: (2018)

Body Muscle-to-Fat Ratio, Rather Than Fat-to-Muscle Ratio, Significantly Correlates With Measured Insulin Resistance in Patients With Type 2 Diabetes Mellitus
por: Kurinami, Noboru, et al.
Publicado: (2021)

Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor
por: Sugiyama, Seigo, et al.
Publicado: (2020)

A Non-obese, Treatment-Naive Japanese Diabetic Patient With Elevated Insulin Clearance and Hyperglycemia Under Enhanced Insulin Sensitivity and Increased Insulin Secretion: Elevated Insulin Clearance as Type 2 Japanese Diabetes Mellitus (T2JDM)
por: Sugiyama, Seigo, et al.
Publicado: (2021)

Reduced Number of Remaining or Healthy Teeth in Patients with Type 2 Diabetes Mellitus: A Cross-sectional Study Assessed by Dentists or Dental Hygienists in Japan
por: Kurinami, Noboru, et al.
Publicado: (2023)

Continuous Glucose Monitoring During Basal–Bolus Therapy Using Insulin Glargine 300 U mL(−1) and Glargine 100 U mL(−1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study
por: Jinnouchi, Hideaki, et al.
Publicado: (2015)

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
por: Ott, Christian, et al.
Publicado: (2017)

Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus
por: Jinnouchi, Hideaki, et al.
Publicado: (2016)

The Authors Reply:
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2013)

An angiotensin II receptor blocker–calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2013)

Combination Treatment of Rosuvastatin or Atorvastatin, with Regular Exercise Improves Arterial Wall Stiffness in Patients with Coronary Artery Disease
por: Toyama, Kensuke, et al.
Publicado: (2012)

Correction: Combination Treatment of Rosuvastatin or Atorvastatin, with Regular Exercise Improves Arterial Wall Stiffness in Patients with Coronary Artery Disease
por: Toyama, Kensuke, et al.
Publicado: (2013)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
por: Karg, M. V., et al.
Publicado: (2018)

SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes
por: Hodrea, Judit, et al.
Publicado: (2022)

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
por: Dobner, Stephan, et al.
Publicado: (2022)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure
por: Berezin, Alexander A., et al.
Publicado: (2022)

Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
por: op den Kamp, Yvo J.M., et al.
Publicado: (2022)

SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways
por: Ma, Li, et al.
Publicado: (2022)

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE(−/−) Mice
por: Leng, Weiling, et al.
Publicado: (2016)

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
por: Nguyen, Thiquynhnga, et al.
Publicado: (2020)

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
por: Nassif, Michael E., et al.
Publicado: (2021)

Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF
por: Fu, Qianyu, et al.
Publicado: (2023)

Low-Dose Aspirin Therapy in Patients With Type 2 Diabetes and Reduced Glomerular Filtration Rate: Subanalysis from the JPAD trial
por: Saito, Yoshihiko, et al.
Publicado: (2011)

Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis
por: Jinnouchi, Hideaki, et al.
Publicado: (2020)

Association between aldehyde dehydrogenase 2 polymorphisms and the incidence of diabetic retinopathy among Japanese subjects with type 2 diabetes mellitus
por: Morita, Kazunori, et al.
Publicado: (2013)

Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy
por: Erdogan, Mumin Alper, et al.
Publicado: (2018)

The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
por: Ohara, Ken, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pcppcbmmu0es1d66lvd624b5tl